Virax Biolabs VRAX
NASDAQ VRAX
$3.19 -0.26 (-7.39%)
As of: Aug 21, 2026 · 3:59 PM EDT

Virax Biolabs (VRAX) Total Debt (2023 - 2026)

Virax Biolabs (VRAX) posted quarterly Total Debt of $28477.0 for Q1 2026, down 12.29% year-over-year from $32468.0 in Q1 2025, and down 12.29% quarter-over-quarter from $32468.0 in Q1 2025.

Virax Biolabs (VRAX) Total Debt (2023 - 2026) Analysis & Trends

Virax Biolabs' Total Debt history runs 3 years deep, the most recent figure standing at $28477.0 for Q1 2026.

  • In Q1 2026, Total Debt fell 12.29% year-over-year to $28477.0; the TTM figure through Mar 2026 stood at $28477.0 (down 12.29% YoY), while the FY2026 annual figure was $28477.0, down 12.29% from the prior year.
  • Total Debt for Q1 2026 stood at $28477.0, down from $32468.0 in the prior quarter.
  • The five-year high for Total Debt was $146250.0 in Q1 2023, with the low at $28477.0 in Q1 2026.
  • The 3-year median for Total Debt is $32468.0 (2025), against an average of $69065.0.
  • Peak annual rise in Total Debt reached 12.29% in 2026, while the deepest fall reached 12.29% in 2026.
  • Virax Biolabs' Total Debt stood at $146250.0 in 2023, then sank by 77.8% to $32468.0 in 2025, then decreased by 12.29% to $28477.0 in 2026.
  • Business Quant data shows VRAX's Total Debt at $28477.0 in Q1 2026, $32468.0 in Q1 2025, and $146250.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 591.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.07 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 770.36 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 546.77 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 9.34 Bn
10 Virax Biolabs 1.31 Mn -5.13 Mn - 265,982.00

Historic Data

Download Data
DateValue
Mar 31, 2026 28,477.00
Mar 31, 2025 32,468.00
Mar 31, 2023 146,250.00